Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5XRMA)

Drug Name

Tipapkinogene sovacivec Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Cervical Intraepithelial neoplasia	2E66.1	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Human papillomavirus protein E6 (HPV E6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VGX-3100	DMMQ2U9	Cervical Intraepithelial neoplasia	2E66.1	Phase 3	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting Human papillomavirus protein E7 (HPV E7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VGX-3100	DMMQ2U9	Cervical Intraepithelial neoplasia	2E66.1	Phase 3	[3]
ADXS-HPV	DMC8NAO	Cervical cancer	2C77.0	Phase 2	[4]
CIGB-228	DMJFPK6	Human papillomavirus infection	1A9Y	Phase 1	[5]
KITE-439	DMUB3H9	Cervical cancer	2C77.0	Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human papillomavirus protein E6 (HPV E6)	TTE2N95	VE6_HPV16	Modulator	[2]
Human papillomavirus protein E7 (HPV E7)	TT3CPZW	VE7_HPV16	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01022346) A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection. U.S. National Institutes of Health.
2	Immune therapy for human papillomaviruses-related cancers
3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4	ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer. Journal for ImmunoTherapy of Cancer, 2013, 1(Suppl 1):P231.
5	Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol. 2011; 2011: 292951.
6	ClinicalTrials.gov (NCT03912831) Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers. U.S. National Institutes of Health.